Theracryf Plc Stock

Equities

EVG

GB00BSVYN304

Biotechnology & Medical Research

Delayed London S.E. 06:59:57 2024-05-23 am EDT 5-day change 1st Jan Change
0.75 GBX 0.00% Intraday chart for Theracryf Plc 0.00% -53.12%
Sales 2024 * 497K Sales 2025 * - Capitalization 4.08M
Net income 2024 * -4M Net income 2025 * -2M EV / Sales 2024 * 3.42 x
Net cash position 2024 * 2.38M Net cash position 2025 * 1.76M EV / Sales 2025 * -
P/E ratio 2024 *
-0.64 x
P/E ratio 2025 *
-1.93 x
Employees 10
Yield 2024 *
-
Yield 2025 *
-
Free-Float 67.58%
More Fundamentals * Assessed data
Dynamic Chart
1 month-6.25%
3 months-28.57%
6 months-55.88%
Current year-53.12%
More quotes
1 week
0.70
Extreme 0.7
0.75
1 month
0.70
Extreme 0.7
0.85
Current year
0.70
Extreme 0.7
2.00
1 year
0.70
Extreme 0.7
4.00
3 years
0.70
Extreme 0.7
9.50
5 years
0.70
Extreme 0.7
20.25
10 years
0.70
Extreme 0.7
45.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO - 23-09-04
Chief Tech/Sci/R&D Officer - 21-04-30
Members of the board TitleAgeSince
Chief Executive Officer 62 -
Chairman 71 14-11-20
Director/Board Member - 15-10-20
More insiders
Date Price Change Volume
24-05-23 0.75 0.00% 186 220
24-05-22 0.75 0.00% 1,586,661
24-05-21 0.75 0.00% 0
24-05-20 0.75 0.00% 371,653
24-05-17 0.75 0.00% 26,775

Delayed Quote London S.E., May 23, 2024 at 06:59 am EDT

More quotes
Theracryf PLC, formerly Evgen Pharma plc, is a clinical-stage therapeutics company. The Company is engaged in developing a new generation of therapeutics in oncology and behavioral brain disorders. Its pipeline and lead compound SFX-01 is derived from its proprietary Sulforadex technology. Its Sulforadex technology synthesizes sulforaphane into an active, stable, and solid form pharmaceutical ingredient, unlocking its medical and commercial potential. SFX-01 is a complex of sulforaphane and alpha-cyclodextrin formulated as a stable tablet. The Company has a candidate orexin 1 antagonist at late preclinical stage targeting addictive behaviors. It also has a candidate molecule DAT inhibitor at late preclinical stage targeting fatigue and narcolepsy.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Annual profits - Rate of surprise